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Introduction
Primary acquisition of drug-resistant HIV at the time of initial infection, referred to as
transmitted drug resistance (TDR), is an underappreciated public health challenge. Of the
estimated 48,600 HIV infections in the U.S. in 2006 [1], approximately 7,100 involved
acquisition of HIV already resistant to ≥1 antiretroviral (ARV) [2]. Two different
mechanisms for TDR have been proposed. In the first, patient in care but sub-optimally
adherent to ARVs acquire resistance mutations [3–6] and transmit them to others. In the
second scenario, viremic persons initially infected with resistant HIV pass it on to recipients
[7] during sexual or needle-sharing risk behavior [8–10]. Both mechanisms likely contribute
to the stable ~10–20% prevalence of TDR seen in North America [11–15] and Europe [16–
19]. Though opinions differ on which is the more significant of the two [7, 20, 21],
opportunities clearly exist for persons already engaged in HIV care to transmit resistant
viruses to others.
Over 70% of HIV-infected persons report some form of sexual activity following their HIV
diagnosis [22], but estimates of the proportion engaging in unprotected sex vary
considerably. As many as 60% of seropositive men and women use condoms inconsistently
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with primary or casual sex partners [22–26]. Investigations into behavioral change following
HIV diagnosis among men who have sex with men (MSM) demonstrate a period of
decreased risk-behavior [27], with half relapsing to unprotected sex within three years [28,
29]. A small but significant proportion of individuals (<5%) report no change in risk
behaviors following diagnosis [29].
Patients who engage in ongoing risk behavior tend to be less adherent to prescribed ARV
regimens [30–34]. This combination of poor ARV adherence and sexual (or injection drug)
risk activity provides a pathway for the transmission of resistance. Evidence suggests that
although this subgroup of non-adherent patients is small, they may contribute
disproportionately to the forward transmission of resistant viruses [32, 34]. We sought to
better characterize the extent to which non-adherent patients contribute to the risk of TDR,
using cross-sectional clinical and behavioral data from the University of North Carolina at
Chapel Hill (UNC) Center for AIDS Research HIV Clinical Cohort (UCHCC). The present
study had two aims: to examine patterns of non-adherence, high-risk sexual behavior,
detectable HIV viremia, and ARV drug resistance and to identify factors associated with
potential transmission of drug-resistant HIV among patients engaged in HIV care.
Methods
Patients and Design
All HIV-infected patients aged ≥18 and receiving HIV care at the UNC Infectious Diseases
Clinic are approached for their willingness to participate in the ongoing, observational
UCHCC study. Written informed consent is obtained from all subjects; <5% of patients
decline participation. Clinical and demographic data are collected through standardized
medical record abstractions at enrollment and every 6 months thereafter. Details about data
collection, laboratory measurements and clinical care were previously described [35]. To
improve capture of social and behavioral data not consistently available in medical records,
UCHCC participants were offered the opportunity to complete a comprehensive,
standardized, face-to-face interview, the Clinical, Sociodemographic and Behavioral Survey
(CSDS), that incorporates multiple validated instruments, including 4-day adherence recall
[36] and alcohol and substance use assessments [37, 38]. The present study is a
retrospective, cross-sectional analysis at the time of interview. If a participant completed
multiple interviews over time, only the most recent was included. Only patients with
complete outcome data were included in our analysis.
Measures
Our primary outcome was a combination of having unprotected sex, detectable HIV viremia,
and evidence of ARV resistance around the time of the interview. We defined unprotected
sex as having ≥1 sex partner in the past six months and not consistently using condoms.
Detectable viremia was defined as HIV RNA ≥400 copies/mL; the level closest to the
interview date was used, within a window beginning 6 months prior and ending one month
thereafter. As HIV RNA assays used during the collection of this data had lower limits of
detection of either 400 or 50, patients with undetectable HIV RNA were assigned average
values of 200 and 25, respectively, for use in calculating viral load distributions.
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Resistance was defined by the 2009 World Health Organization list of surveillance drug
resistance mutations (SDRMs) [39], a curated list specifically created for epidemiological
analyses of TDR prevalence [40]. Genotypic resistance tests (GRTs) conducted prior to or
on the interview day were included.
Two interview questions concerned ARV adherence: “How many doses have you missed in
the last 4 days: 0, 1, or 2 or more?” and “Thinking about the past 4 weeks, on average how
would you rate your ability to take all of your HIV medications as your doctor prescribed:
excellent, very good, good, fair, poor or very poor?” We considered ≥1 missed dose in the
prior 4 days as not adherent. “Very good” and “good” were grouped together, as were “fair,”
“poor,” and “very poor.”
Statistical analyses
Demographic, behavioral and clinical variables were described, and associations with
unprotected sex and presence of a known SDRM were assessed. Wilcoxon rank-sum tests
were used to compare continuous variables and Pearson’s χ2 test was used for categorical
variables, with exact P values calculated where appropriate. Statistical significance was
defined as P <0.05.
Based on the number of sexual partners, condom utilization, HIV RNA detectability, and
presence of any SDRM, we constructed a flow chart to help define those individuals at
greater risk of transmitting drug resistance to others. Log-linear binomial regression models
were used to calculate prevalence ratios (PR) and 95% confidence intervals (CI) associated
with predictors of membership in this high-risk group. Bivariate associations with P values
<0.1 were considered for inclusion in the multivariable analysis. All analyses were
performed with SAS (version 9.3, SAS Institute, Cary, NC, USA).
A number of sensitivity analyses were performed. Because patients may underestimate the
number of partners or overestimate condom utilization, a bounded analysis was conducted to
assess the range in the proportion of the study population at risk for transmitting drug-
resistant HIV. Regression models were repeated to examine if predictors remained the same
with the expanded definition of the high-risk group.
Ethics approval
The UNC Institutional Review Board previously approved the UCHCC and CSDS, which
also covered associated secondary data analyses.
Results
Demographics
Of 482 unique face-to-face interviews completed between 2000–2011, 244 met inclusion
criteria (Supplemental Figure). Median age was 43 years (range, 19–74; Table 1), and 37%
were female. Non-white participants represented 79% of the sample; Blacks accounted for
70%. A majority had at least a high school education, and 13% were college graduates. One
fifth of respondents described being homeless at some point since their HIV diagnosis.
Thirty-eight percent were MSM (60% of male respondents). Thirty-two percent of included
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patients were interviewed in 2000–2003; 19% in 2004–2006; and 50% in 2007–2011.
Demographics of interviewees were very similar to the overall UCHCC [35]. Patients
excluded from analysis due to incomplete data did not differ demographically, but had fewer
diagnoses of clinical AIDS, higher CD4 counts, and less ARV experience than those
included in analysis (Supplemental Tables 1 and 2).
Clinical characteristics
Median time from HIV diagnosis to interview was 8 years (range, 0.1–21.9; Table 2), with
28% meeting a clinical definition of AIDS during their care. Median CD4 count among
interviewees was 426 cells/µL (range, 9–1496), and 59% had HIV RNA viral loads below
400 copies/mL. Eighty-four percent of the group were on ARVs, with a median of 6.7 years
since their first regimen was prescribed (range, 0.1–20.4). Forty-four percent of participants
were heavily treatment experienced, with exposure to >4 ARV regimens. Only 8 were ARV-
naïve (3%).
Depression and substance use
Just over half had a history of depression (Table 1). Thirty-eight percent of participants
noted active substance use at the time of the interview. Marijuana (23%) and crack cocaine
(19%) were most common; injection drug use was rare (n=2, 0.8%). Only 9% of respondents
used alcohol heavily, defined as consumption ≥4 times per week.
Adherence
Among the 204 participants on ARVs when interviewed, 58% self-reported “excellent”
adherence (Table 2). Eight percent missed ≥2 doses in the prior 4 days. Viral loads were
strongly associated with adherence; 80% of those self-reporting “excellent” adherence had
undetectable HIV RNA, compared to 48% and 24% among those with “good” and “poor”
adherence, respectively (P<0.01).
Sexual behavior and condom utilization
Seventy percent of subjects reported some sexual activity in the prior six months (n=172);
among these, 23% had 2–4 partners (n=39), and 6% reported >4 partners (n=10). Nearly
two-thirds of sexually active participants reported vaginal sex (56 women, 49 men), with 65
(61%) indicating they used a condom “all of the time” for vaginal intercourse. Three women
and 56 men had anal sex; only 49% consistently used condoms.
Factors associated with unprotected sexual activity
Participants reporting unprotected sex were younger than those who either consistently used
condoms or were abstinent (41 versus 45 years, P < 0.01; Table 1). No gender differences
existed in frequency of unprotected sex, but MSM were more likely to report unprotected
sexual activity than heterosexual males (P=0.04). Unprotected sex was more common
among active substance users (P=0.04), and we observed non-significant trends toward more
unprotected sex among whites and Native Americans (P=0.40).
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Persons with a clinical history of AIDS were less likely to report unprotected intercourse
(P<0.01; Table 2). Median viral loads were higher among interviewees reporting
unprotected sex (295 copies/mL, interquartile range [IQR], 25–13000) compared to those
who consistently used condoms or were abstinent (62 copies/mL, IQR, 25–3687; P=0.04).
Suboptimal adherence was nonsignificantly associated with unprotected sexual activity.
Among individuals who reported unprotected sex, 20% missed at least one ARV dose in the
prior 4 days, compared with 13% among those not engaging in unprotected sex (P =0.12).
Those with self-assessed “good” or “poor” adherence were more likely to have unprotected
intercourse than those with “excellent” adherence (P=0.33).
Prevalence of drug-resistance mutations
One hundred thirty-one study participants (54%) had ≥1 SDRM (Figure 1) – including 12
ARV-naïve individuals with any SDRM at entry to care. The most frequently observed
reverse transcriptase mutation was M184V, seen in 94 subjects (39%). K103N and K70R
were also frequently detected (23% and 13% prevalence, respectively). The most common
protease mutations were L90M (9%) and I54V (7%). Overall, 45% harbored SDRMs for
NRTIs (n=110), 31% had NNRTI resistance (n=76), and 23% had PI resistance (n=56).
Triple-class resistance was noted in 26 cases (11%).
Factors associated with drug-resistance mutations
Age, sex and race were not associated with having SDRMs (Table 1). However, those with a
history of homelessness, depression, or active cocaine use were more likely to have
resistance (all P≤0.04). Participants with a longer time since HIV diagnosis, a longer time on
ARVs, or a greater number of regimens were more likely to have an SDRM (all P<0.01).
Compared to poorly adherent participants, those with excellent adherence harbored SDRMs
less often (86% vs. 51%; P=0.03). The proportion with newly identified resistance decreased
over time (P=0.1).
Potential transmission of drug resistance
As shown in Figure 2, 70% reported sexual activity in the prior 6 months, and a majority
used condoms inconsistently (n=94). Among the 44 subjects with inconsistent condom use
and HIV RNA >400 copies/mL, 30 had documented resistance (12% of the subset). Viremia
in this high-risk group was significant; 90% had HIV RNA >1500 copies/mL. Nine subjects
had single-class resistance, 14 had dual-class, and 7 had triple-class SDRMs.
In bivariate analyses (Table 3), we found that subjects who completed some college
education had a two-fold greater prevalence in the high-risk group (PR 2.03, 95% CI, 1.02,
4.02) and noted a non-significant trend toward a greater prevalence of MSM (PR 1.89, 95%
CI, 0.97, 3.69). However, in bivariate and multivariate analyses, substance use and
homelessness emerged as having the two strongest associations with membership in the
high-risk group. Participants who used any illicit substance in the prior year or who reported
heavy alcohol use had a three-fold greater prevalence in the high-risk group than non-users
(adjusted PR [aPR] 3.12, 95% CI, 1.47, 6.62). Interviewees who reported any homelessness
since HIV diagnosis had an adjusted high-risk group prevalence 2.2 times that of individuals
with continuous housing (95% CI, 1.16, 4.18).
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Participant underestimation of sexual activity and/or overestimation of condom use would
alter the proportion categorized into our defined high-risk group. Considering all patients
with detectable drug-resistant viremia as members of our high-risk group increased the size
of this group to 56, or 23% of those with complete data. Our findings were consistent using
this expanded high-risk group definition, with substance abuse (aPR 1.82, 95% CI, 1.15,
2.88) and homelessness since HIV diagnosis (aPR 1.99, 95% CI, 1.28, 3.10) remaining
associated with risk of transmitting ARV resistance to others.
Discussion
Given revised U.S. treatment guidelines advocating ARV initiation for all HIV-infected
persons regardless of CD4 count [41] and a shift toward “test, link, and treat” models of
HIV care[42], we are poised to see greater numbers of patients on therapy in the coming
years. With this increase in the number of people taking ARVs, we will likely observe an
increase in the number of non-adherent patients engaged in sexual risk behavior – even if the
proportions of such patients observed in our study (12%) and other cohorts (5–20%) [31–34]
remain unchanged. Since this group may contribute disproportionately to transmission of
resistant HIV [32], an expansion of TDR could be seen over time. Thus, improving our
understanding of potential sources of TDR is perhaps more important than ever before.
In our cross-sectional study of HIV-infected patients in care, we observed all the requisite
factors needed for sexual transmission of resistant HIV to occur. Forty percent reported
suboptimal adherence to their ARVs. Nearly 60% of sexually active participants had
unprotected sex at least once in the previous 6 months and tended to be younger and active
substance users. The presence of an SDRM was associated with active cocaine use, a history
of homelessness since HIV diagnosis, depression, and poor ARV adherence. Finally, we
found the risk of having an opportunity to transmit resistant HIV was doubled by a history
of homelessness and tripled by active substance use. The relationship of homelessness to the
presence of ARV mutations and potential TDR has not been previously reported, but
housing instability is a recognized contributor to poorer adherence [43].
These findings add to the limited existing literature on the potential for sexual transmission
of resistant HIV among patients in care. Because poor adherence often leads to the
development of ARV resistance [3], studies of opportunities for TDR have primarily
examined the link between non-adherence and sexual risk behavior. Several clinic-based
cohort studies in the United States have shown that the odds of high-risk sexual behavior are
increased 1.5–2.5 times among patients with suboptimal ARV adherence, despite significant
differences among the studies in terms of demographics, geography, and participant
behaviors [30, 31, 34, 44]; the prevalence of patients in this group ranged from 8.5% [34] to
18% [31]. Three additional studies took a more direct approach, focusing on patients with
genotypically-proven ARV resistance who reported high-risk behavior. Kozal et al. studied
333 patients in care (but not necessarily taking ARVs) and found 23% reported unprotected
anal or vaginal sex in the prior 3 months; among these, 18 had resistance, for an overall
prevalence of 4.5% [32]. Notably, this small subset reported 207 sexual events in the recall
period, 80% of which were unprotected – providing evidence that a few individuals might
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account for a disproportionately large number of potential transmission events. Chin-Hong
et al. evaluated 279 patients in San Francisco, noting 17% of MSM and 6% of heterosexual
men and women with resistant viruses had unprotected sex with serodiscordant or status-
unknown partners in the prior 4 months [33]. Finally, at 14% of encounters with members of
a Baltimore IDU cohort, participants with significant ARV resistance described unprotected
sex and/or needle-sharing during periods of incomplete virological suppression on ARVs
[45].
Clearly, not every patient who develops resistance has unprotected sex. However, the
strength of this association – observed across multiple, diverse clinical cohorts – suggests
that non-adherence and the accumulation of resistance could serve as a marker of coincident
sexual risk behavior. Since many HIV providers check HIV RNA more often than they
update a patient’s sexual history [46], any detectable viremia should prompt a discussion
with the patient about not only adherence, but also transmission risk behavior. Targeted
interventions to reduce sexual partner number and improve condom utilization among
patients with new or documented resistance could be important first steps toward reducing
the spread of TDR. Finally, the role of substance abuse as a factor in both non-adherence
and transmission risk cannot be underestimated; appropriate treatment for addiction is
essential for preventing resistance and reducing high-risk sexual behaviors.
Our study is not without limitations. Only 250 of 482 participants completing face-to-face
interviews had ever undergone resistance testing (52%). We felt the likelihood was low that
undocumented mutations were present among the 232 who never had a GRT, since our
institutional practice has long been to check for resistance in the setting of treatment failure.
Social desirability bias during the face-to-face interview may have led participants to
underestimate the number of sexual partners or overestimate adherence, but we explored this
with our bounded sensitivity analysis and found similar factors associated with our primary
outcome. Finally, our composite primary outcome reflects the factors necessary for
transmission of resistant HIV to occur; it is impossible to know what viruses were
circulating in the blood or genital tract at exactly the time of potential transmission events.
In summary, we found a small but significant proportion of clinic patients with viremia and
documented resistant HIV continue to engage in sexual behaviors that place others at risk
for TDR. Clinic-based, targeted secondary prevention and adherence interventions could
substantially reduce opportunities for forward transmission of resistant HIV in the future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Results of genotypic resistance testing among 244 participants in the UNC CFAR HIV
Clinical Cohort. Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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Flow diagram of risk factors for transmitting drug-resistant HIV among 244 participants in
the UNC CFAR HIV Clinical Cohort.a Detectable HIV RNA was defined as ≥400
copies/mL.b Antiretroviral (ARV) resistance was defined as the presence of ≥1 surveillance
drug resistance mutation [39].
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Table 3
Associations between demographic and clinical characteristics and risk for transmitting drug resistant HIV, in






Age (per 10 year increase) 1.00 (0.99, 1.00) .13
Sex
  Female 1.0
  Male 1.95 (0.87, 4.37) .10
Race
  Black 1.0
  White 1.05 (0.47, 2.31) .91
  Other 0.37 (0.05, 2.61) .32
Education
  < HS or HS grad 1.0
  Some college 2.03 (1.02, 4.02) .04
  College grad or post-grad 0.63 (0.15, 2.65) .53
Homelessnessb
  Yes 2.82 (1.47, 5.43) <.01 2.20 (1.16, 4.18) .02
  No 1.0 1.0
Man who has sex with men
  Yes 1.89 (0.97, 3.69) .06 1.75 (0.93, 3.28) .08
  No 1.0 1.0
Depressionc
  Yes 1.42 (0.71, 2.85) .33
  No 1.0
Substance used
  Yes 3.86 (1.85, 8.05) <.01 3.12 (1.47, 6.62) <.01
  No 1.0 1.0
Years since HIV diagnosis
  <3 0.20 (0.03, 1.44) .11
  3–10 1.0
  11–15 1.54 (0.76, 3.09) .23
  16+ 0.57 (0.14, 2.33) .43
History of clinical AIDS
  Yes 1.50 (0.75, 2.98) .25
  No 1.0
Abbreviations: AIDS, acquired immune deficiency syndrome; CFAR, Center for AIDS Research; HIV, human immunodeficiency virus; HS, high
school; PR, prevalence ratio; SDRM, surveillance drug resistance mutation; UNC, University of North Carolina.
a
Statistical significance defined as P <0.05 for all tests.
b
Homeless at any time since HIV diagnosis.
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c
A diagnosis of depression listed in the patient’s medical chart at any point prior to the interview.
d
Substance use was defined as drinking alcohol 4 or more times per week, or regular consumption of any illegal drugs in the year prior to
interview.
AIDS. Author manuscript; available in PMC 2014 November 28.
